Indian CRO GVK Biosciences has become a global player since Sequoia Capital first bought a stake back in 2007, and now the venture capital stalwart is looking to sell its share at more than three times the price, according to The Economic Times.
MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.
In the CRO world, the fight to secure contracts and strategic partnerships often comes down to expertise, and Quintiles, the industry's largest outfit, believes it has a serious competitive advantage. The North Carolina CRO said it employs twice as many M.D.s and Ph.D.s as any of its competitors, giving it a leg up in the changing world of science.
As demand for biosimilar development swells around the world, CRO inVentiv Health has teamed up with Australia's Proteomics International to expand its characterization services, an effort to boost its capabilities in early work on biologic knockoffs.
Charles River Laboratories is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money.
European private equity outfit Cinven has stepped up to buy the majority of long-rumored target Medpace, trading $915 million for an undisclosed controlling stake in the CRO.
PPD has signed a deal with a German hospital to help bring more clinical trials to the country, agreeing to lend its global reach and help lure drug developers.
Global Genomics Group is in the midst of an expansive cardiovascular study with hopes of finding new biomarkers and drug targets for coronary artery disease, and now the company has enlisted the help of CRO giant Quintiles to handle some of the necessary gene sequencing work.
Global CRO Parexel International is looking to expand its regulatory consulting, launching a dedicated unit focused on the post-approval needs of drug and medical device developers.
Icon watched its revenue swell by 20% last year, and now the Irish CRO is expecting a healthy rate of new business wins to fuel growth in 2014.
CRO Theorem Clinical Research has struck a deal with a healthcare analytics firm, giving it access to economics and outcomes research technology the company said can help drug developers make the right decisions throughout the R&D process.
CRO Chiltern has hooked up with Karolinska Development, signing on to run clinical trials for the group's many projects.
Capping off a year in which it raised nearly $950 million in an up-sized IPO, Quintiles hauled in $1 billion in service revenue in the fourth quarter, a company first that sets the table for more growth in 2014.
Last year, Albany, NY, contract developer AMRI watched its founding CEO retire and its business model evolve, shifting its priorities to deliver a jump in revenue, and now the company believes it's on track for bigger growth in 2014.
Almost 10 years after closing a deal for the eClinical-focused Perceptive Informatics, CRO giant Parexel International is grafting its own name onto the subsidiary, part of a sweeping rebranding effort the company hopes will help nail down more partnerships.
Charles River Laboratories has pulled off a sweeping reorganization over the past few years, and the effort returned the preclinical CRO to revenue growth in 2013, setting the stage for another jump this year.
The global CRO market is likely to hit $23.6 billion this year, according to Industry Standard Research, an all-time high that will only be followed by faster growth.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.
Last year, CRO BioClinica saw its most rapid growth in Europe, the company said, and now, as it prepares to join forces with CCBR-Synarc in its second merger in as many years, the clinical trial outfit plans to deepen its investment in the continent.